Edition:
India

Santhera Pharmaceuticals Holding AG (SANN.S)

SANN.S on Swiss Exchange

16.80CHF
22 Jun 2018
Change (% chg)

CHF0.20 (+1.20%)
Prev Close
CHF16.60
Open
CHF16.90
Day's High
CHF17.60
Day's Low
CHF16.62
Volume
45,367
Avg. Vol
22,628
52-wk High
CHF74.00
52-wk Low
CHF16.12

Latest Key Developments (Source: Significant Developments)

Santhera: MHRA Renews Early Access Option For Raxone For Duchenne
Friday, 22 Jun 2018 

June 22 (Reuters) - Santhera Pharmaceuticals Holding AG ::UK'S MHRA RENEWS EARLY ACCESS TO MEDICINES SCHEME SCIENTIFIC OPINION FOR SANTHERA'S RAXONE® (IDEBENONE) IN DUCHENNE MUSCULAR DYSTROPHY.  Full Article

Santhera Pharmaceuticals Holding 2017 Revenues From Sales Of Raxone Up At CHF 22.9 Million
Monday, 29 Jan 2018 

Jan 29 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG ::INCREASE OF 21% YOY IN FY NET REVENUES TO CHF 22.9 MILLION (2016: CHF 19.0 MILLION) FROM SALES OF RAXONE.FOR 2017, SANTHERA ANTICIPATES A NET RESULT OF CHF -50 TO -55 MILLION..FOR 2018 EXPECTS NET SALES OF RAXONE FOR CURRENTLY APPROVED INDICATION LHON TO REACH CHF 28 TO 30 MILLION.  Full Article

Santhera successfully places 60 mln Swiss francs senior convertible bonds
Friday, 10 Feb 2017 

Santhera Pharmaceuticals Holding AG :Santhera successfully places 60 million Swiss francs ($59.67 million) senior convertible bonds.  Full Article

Santhera launches senior convertible bond issue
Friday, 10 Feb 2017 

Santhera Pharmaceuticals Holding AG : Santhera launches senior convertible bond issue . To launch of an offering of 50 million Swiss francs ($49.89 million) senior unsecured convertible bondsdue 2022 with possibility of an increase by a maximum of 10 million francs to 60 million francs .Convertible bonds have a 5-year maturity, are expected to carry a coupon of between 4.5 percent and 5.0 percent per annum.  Full Article

Santhera announces appointment of Kristina Timdahl as Chief Medical Officer
Tuesday, 4 Oct 2016 

Santhera Pharmaceuticals Holding AG : Santhera announces appointment of Kristina Timdahl as Chief Medical Officer and head of development as of January 2017 .Will replace Nick Coppard, who will retire in January 2017.  Full Article

Santhera Pharmaceuticals Holding H1 net loss widens to CHF 18 million
Tuesday, 6 Sep 2016 

Santhera Pharmaceuticals Holding AG : As of June 30, 2016, Santhera had cash and cash equivalents of 63.6 million Swiss francs ($64.89 million) (December 31, 2015: 76.9 million francs) . H1 operating loss amounted to 17.2 million francs (H1 2015: -6.2 million francs) leading to a net result of -18.0 million francs (H1 2015: -6.4 million francs) .Expects net sales of Raxone in 2016 to reach 16 to 18 million francs.  Full Article

Santhera Pharmaceuticals Holding updates on U.S. regulatory filing for Raxone
Thursday, 14 Jul 2016 

Santhera Pharmaceuticals Holding AG : Announces that it has received written correspondence from U.S. Food and Drug Administration (FDA) on its proposed subpart H approval pathway for Raxone in DMD patients not taking concomitant glucocorticoids .FDA concluded that results from SIDEROS trial, should be provided at time of filing to support an NDA for treatment of DMD patients irrespective of their glucocorticoid use status.  Full Article

Swiss stocks - Factors to watch on June 22

ZURICH, June 22 The Swiss blue-chip SMI was seen opening 0.2 percent higher at 8473 points on Friday, according to premarket indications by bank Julius Baer .